Camille Couffignal1, François Desgrandchamps2, Pierre Mongiat-Artus2, Vincent Ravery3, Idir Ouzaid3, Morgan Roupret4, Véronique Phe5, Calin Ciofu6, Florence Tubach7, France Mentre1, Olivier Cussenot8, Bernard Grandchamp9. 1. INSERM, IAME, UMR 1137, Paris, France; University Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Department of Biostatistics, Bichat Hospital, Paris, France. 2. AP-HP, Department of Urology, Saint Louis Hospital, Paris, France. 3. AP-HP, Department of Urology, Bichat Hospital, Paris, France. 4. GRC-05, University Institute of Cancerology (IUC), Departments of Urology Tenon and Pitié Hospitals, University Paris-6, Paris, France; AP-HP, Department of Urology, Pitié Hospital, Paris, France. 5. AP-HP, Department of Urology, Pitié Hospital, Paris, France. 6. AP-HP, Department of Urology, Tenon Hospital, Paris, France. 7. INSERM, ECEVE, UMR 1123, CIC-EC 11425, Paris, France; ECEVE, UMR 1123, University of Paris Diderot, Sorbonne Paris Cité, Paris, France; AP-HP, Department of Epidemiology and Clinical Research, Bichat Hospital, Paris, France. 8. GRC-05, University Institute of Cancerology (IUC), Departments of Urology Tenon and Pitié Hospitals, University Paris-6, Paris, France; AP-HP, Department of Urology, Tenon Hospital, Paris, France. 9. AP-HP, Department of Genetics, Bichat Hospital, Paris, France. Electronic address: bernard.grandchamp@bch.aphp.fr.
Abstract
OBJECTIVE: To assess the diagnostic and prognostic performance of a noninvasive FGFR3 mutation analysis. After transurethral resection (TUR) of noninvasive bladder transitional cell carcinoma (B-TCC), recurrence occurs in 70% of patients, thus justifying cystoscopic surveillance. MATERIALS AND METHODS: A prospective multicenter study was carried out with a 2-year follow-up of patients with superficial B-TCC. Urine samples were collected before TUR and then before each cystoscopy during follow-up. Screening for the most prevalent FGFR3 mutations was done using urinary cells. The prognostic significance of an FGFR3 mutation at the time of the initial diagnosis was determined. The performance of the test in diagnosing and/or predicting recurrence during follow-up was assessed by calculating sensitivity and specificity. RESULTS: Of 191 patients studied, 74 (39%) had a positive analysis before TUR (FGFR3 mutation group). The presence of an FGFR3 mutation at the time of diagnosis was associated with a shorter time to recurrence (P = .02). During follow-up, 68 patients from the FGFR3 mutation group were evaluated. FGFR3 mutation analysis showed a sensitivity of 0.73 and a specificity of 0.87 when compared with the results of cystoscopy. A positive urine test was predictive of recurrence either at the time of the positive result or later during the 2-year follow-up, with a sensitivity of 0.70 and a specificity of 0.87. CONCLUSION: Among patients with an FGFR3 mutation in the initial tumor, a noninvasive urine test during follow-up can be valuable in diagnosing or predicting subsequent recurrence.
OBJECTIVE: To assess the diagnostic and prognostic performance of a noninvasive FGFR3 mutation analysis. After transurethral resection (TUR) of noninvasive bladder transitional cell carcinoma (B-TCC), recurrence occurs in 70% of patients, thus justifying cystoscopic surveillance. MATERIALS AND METHODS: A prospective multicenter study was carried out with a 2-year follow-up of patients with superficial B-TCC. Urine samples were collected before TUR and then before each cystoscopy during follow-up. Screening for the most prevalent FGFR3 mutations was done using urinary cells. The prognostic significance of an FGFR3 mutation at the time of the initial diagnosis was determined. The performance of the test in diagnosing and/or predicting recurrence during follow-up was assessed by calculating sensitivity and specificity. RESULTS: Of 191 patients studied, 74 (39%) had a positive analysis before TUR (FGFR3 mutation group). The presence of an FGFR3 mutation at the time of diagnosis was associated with a shorter time to recurrence (P = .02). During follow-up, 68 patients from the FGFR3 mutation group were evaluated. FGFR3 mutation analysis showed a sensitivity of 0.73 and a specificity of 0.87 when compared with the results of cystoscopy. A positive urine test was predictive of recurrence either at the time of the positive result or later during the 2-year follow-up, with a sensitivity of 0.70 and a specificity of 0.87. CONCLUSION: Among patients with an FGFR3 mutation in the initial tumor, a noninvasive urine test during follow-up can be valuable in diagnosing or predicting subsequent recurrence.
Authors: Jean-Pierre Roperch; Bernard Grandchamp; François Desgrandchamps; Pierre Mongiat-Artus; Vincent Ravery; Idir Ouzaid; Morgan Roupret; Véronique Phe; Calin Ciofu; Florence Tubach; Olivier Cussenot; Roberto Incitti Journal: BMC Cancer Date: 2016-09-01 Impact factor: 4.430
Authors: Young Kwang Chae; Keerthi Ranganath; Peter S Hammerman; Christos Vaklavas; Nisha Mohindra; Aparna Kalyan; Maria Matsangou; Ricardo Costa; Benedito Carneiro; Victoria M Villaflor; Massimo Cristofanilli; Francis J Giles Journal: Oncotarget Date: 2017-02-28
Authors: Feng Zhu; Yan Zhang; Lei Shi; Chun-Lei Wu; Shuai-Qi Chen; Hang Zheng; Dong-Kui Song Journal: Medicine (Baltimore) Date: 2019-08 Impact factor: 1.817
Authors: Marianna A Zolotovskaia; Maxim I Sorokin; Ivan V Petrov; Elena V Poddubskaya; Alexey A Moiseev; Marina I Sekacheva; Nicolas M Borisov; Victor S Tkachev; Andrew V Garazha; Andrey D Kaprin; Peter V Shegay; Alf Giese; Ella Kim; Sergey A Roumiantsev; Anton A Buzdin Journal: Int J Mol Sci Date: 2020-02-26 Impact factor: 5.923